{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:39:25Z","timestamp":1794623965145,"version":"4.9.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,3]]},"DOI":"10.7759\/cureus.49867","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T10:57:26Z","timestamp":1701601046000},"source":"Crossref","is-referenced-by-count":8,"title":["Exploring Pembrolizumab-Induced Myocarditis, Myositis, and Myasthenia Gravis: A Comprehensive Literature Review and Case Presentation on Bladder Cancer"],"prefix":"10.7759","author":[{"given":"Divya","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma","volume":"8","author":"Raedler LA","year":"2015","unstructured":"Raedler LA. Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits. 2015, 8:96-100.","journal-title":"Am Health Drug Benefits"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo M","year":"2020","unstructured":"Todo M, Kaneko G, Shirotake S, et al.. Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. IJU Case Rep. 2020, 3:17-20. 10.1002\/iju5.12128","journal-title":"IJU Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2019.12.023","article-title":"Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1\u00a0: case report and literature review [Article in French]","volume":"41","author":"Prevel R","year":"2020","unstructured":"Prevel R, Colin G, Cal\u00e8s V, Renault PA, Mazieres J. Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1\u00a0: case report and literature review [Article in French]. Rev Med Interne. 2020, 41:284-8. 10.1016\/j.revmed.2019.12.023","journal-title":"Rev Med Interne"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi E","year":"2023","unstructured":"Raschi E, Rossi S, De Giglio A, Fusaroli M, Burgazzi F, Rinaldi R, Potena L. Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians. Drug Saf. 2023, 46:819-33. 10.1007\/s40264-023-01320-5","journal-title":"Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/209646-exploring-pembrolizumab-induced-myocarditis-myositis-and-myasthenia-gravis-a-comprehensive-literature-review-and-case-presentation-on-bladder-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:11:36Z","timestamp":1707491496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/209646-exploring-pembrolizumab-induced-myocarditis-myositis-and-myasthenia-gravis-a-comprehensive-literature-review-and-case-presentation-on-bladder-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,3]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.49867","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,3]]}}}